Abbott Again Moves To Block Generic Version Of Zemplar
Abbott Laboratories on Wednesday again went to court to defend its Zemplar injectable, accusing Strides Arcolab Ltd. of developing a generic version of the kidney disease treatment that infringes Abbott's patents....To view the full article, register now.
Already a subscriber? Click here to view full article